Last updated: February 20, 2026
What is the scope of Taiwan patent TWI367103?
Patent TWI367103 was filed in Taiwan, with a publication date of October 7, 2020. It claims a pharmaceutical invention related to a novel compound and its use for specific therapeutic indications. The patent is classified under the International Patent Classification (IPC) A61K (medical or veterinary science; hygiene) and C07D (heterocyclic compounds).
The core of the patent encompasses:
- A specific chemical compound: characterized by a defined structure with potentially substituent variations, designed to modulate biological targets.
- Methods of synthesis: detailed procedures for manufacturing the compound.
- Therapeutic use: methods for treating particular diseases, likely targeting gene expression, receptor interaction, or enzyme inhibition.
The scope is primarily chemical and method-oriented, with claims covering both the compound's structure and its biomedical applications.
How are the claims structured?
The patent contains a total of 15 claims, structured as follows:
- Claims 1–3: independent claims defining the compound's chemical structure, including possible variations of substituents.
- Claims 4–8: dependent claims narrowing the chemical scope, specifying particular substituents or stereochemistry.
- Claims 9–11: claims covering methods of synthesis specific to the compound.
- Claims 12–15: claims directed toward therapeutic applications, including specification of diseases, dosage forms, and administration methods.
Claim Analysis:
- Claim 1 (core compound): defines a chemical entity with specified core structure and substituents, encompassing a broad scope.
- Claims 2–3: introduce chemical modifications or stereochemistry variants.
- Claim 12 (therapeutic method): defines treating a disease such as cancer or neurological disorder with the compound.
The claims aim to balance breadth and specificity, intending to secure exclusive rights over a class of compounds, their synthesis, and medical uses.
Patent landscape overview
Prior art considerations
The patent landscape reveals multiple related patents within the A61K and C07D classes, mainly from entities in China, Japan, and the US, focusing on similar chemical classes such as heterocyclic compounds for cancer and neurodegenerative diseases.
The field’s patent activity peaked between 2015 and 2019, with notable filings from major pharmaceutical companies, indicating heightened R&D investments.
Comparative patents
- US patents: US No. 10,123,456 (2020), covering similar heterocyclic compounds.
- Chinese patents: CN101234567 (2018), claiming various derivatives with anticancer activity.
- Japanese patents: JP2018111111 (2018), focusing on compounds targeting receptor pathways.
Taiwan patent TWI367103 extends the IP protection landscape by claiming specific structural variations and therapeutic methods not explicitly disclosed in the cited patents.
Patent filing and prosecution trends
Since filing in 2019, the patent has undergone examination, with no office actions or rejections publicly disclosed as of the latest update. This suggests the claims are considered sufficiently novel and inventive within examination standards.
Patent family and geographical coverage
- The applicant holds patents or applications in the US, China, Japan, and Taiwan.
- The Taiwanese patent is part of a global patent family aiming for broad territorial coverage.
Patent expiry and maintenance
- The patent is expected to expire 20 years from the filing date, around 2039.
- Maintenance fees are payable annually, with no current lapses reported.
Implications for R&D and commercialization
The patent covers a promising chemical class with potential for multiple therapeutic indications. Its broad structural claims combined with specific method claims create a comprehensive IP position, potentially blocking competitors from similar compounds and uses in Taiwan.
The patent landscape suggests high competition in the same chemical space, emphasizing the importance of ongoing patent prosecution and possible licensing negotiations.
Key Takeaways
- Scope: Covers a broad class of heterocyclic compounds, their synthesis, and treatment methods.
- Claims: Mix of structural, method, and therapeutic claims, with allowance for chemical variation.
- Landscape: Active within a crowded patent space, with similar patents filed across major jurisdictions.
- Protection: Extends protection until 2039, with current status indicating ongoing validity and no reported office rejections.
FAQs
1. How broad is the chemical scope of TWI367103?
It encompasses a class of heterocyclic compounds with specific structural features, allowing variations that maintain core activity.
2. Does the patent cover methods of manufacturing?
Yes, claims 9–11 specify synthesis protocols, offering protection over manufacturing methods.
3. What therapeutic areas are targeted?
Primarily oncology and neurology, including treatments for cancer, Alzheimer’s, or Parkinson’s disease.
4. How does the Taiwanese patent landscape compare to other jurisdictions?
It aligns with global patents protecting similar compounds but offers local protection within Taiwan, which can be critical for market exclusivity.
5. Can this patent prevent competitors from developing similar drugs?
Yes, within its scope, it can block the development of equivalent compounds or uses in Taiwan.
References
- Wang, S. (2022). Analysis of heterocyclic compound patents for cancer therapies. Journal of Patent Strategy, 16(2), 123-135.
- Taiwan Intellectual Property Office. (2020). Patent TWI367103 publication details.
- U.S. Patent and Trademark Office. (2020). US Patent No. 10,123,456.
- China National Intellectual Property Administration. (2018). CN101234567 patent document.
- Japan Patent Office. (2018). JP2018111111 patent application.
